212 related articles for article (PubMed ID: 7989485)
1. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid.
Paschke R; Tonacchera M; Van Sande J; Parma J; Vassart G
J Clin Endocrinol Metab; 1994 Dec; 79(6):1785-9. PubMed ID: 7989485
[TBL] [Abstract][Full Text] [Related]
2. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades.
Parma J; Van Sande J; Swillens S; Tonacchera M; Dumont J; Vassart G
Mol Endocrinol; 1995 Jun; 9(6):725-33. PubMed ID: 8592518
[TBL] [Abstract][Full Text] [Related]
3. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma.
Tonacchera M; Chiovato L; Pinchera A; Agretti P; Fiore E; Cetani F; Rocchi R; Viacava P; Miccoli P; Vitti P
J Clin Endocrinol Metab; 1998 Feb; 83(2):492-8. PubMed ID: 9467563
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutations in the VI transmembrane segment of the thyrotropin receptor constitutively activate cAMP signalling in thyroid hyperfunctioning adenomas.
Porcellini A; Ciullo I; Pannain S; Fenzi G; Avvedimento E
Oncogene; 1995 Sep; 11(6):1089-93. PubMed ID: 7566968
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas.
Parma J; Duprez L; Van Sande J; Cochaux P; Gervy C; Mockel J; Dumont J; Vassart G
Nature; 1993 Oct; 365(6447):649-51. PubMed ID: 8413627
[TBL] [Abstract][Full Text] [Related]
6. Thyrotropin receptor mutations in hyperfunctioning thyroid adenomas from Brazil.
Nogueira CR; Kopp P; Arseven OK; Santos CL; Jameson JL; Medeiros-Neto G
Thyroid; 1999 Nov; 9(11):1063-8. PubMed ID: 10595453
[TBL] [Abstract][Full Text] [Related]
7. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas.
Parma J; Duprez L; Van Sande J; Hermans J; Rocmans P; Van Vliet G; Costagliola S; Rodien P; Dumont JE; Vassart G
J Clin Endocrinol Metab; 1997 Aug; 82(8):2695-701. PubMed ID: 9253356
[TBL] [Abstract][Full Text] [Related]
8. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas.
Russo D; Arturi F; Suarez HG; Schlumberger M; Du Villard JA; Crocetti U; Filetti S
J Clin Endocrinol Metab; 1996 Apr; 81(4):1548-51. PubMed ID: 8636365
[TBL] [Abstract][Full Text] [Related]
9. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism.
Paschke R
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():129-32. PubMed ID: 8981020
[TBL] [Abstract][Full Text] [Related]
10. Identification and functional characterization of two novel activating thyrotropin receptor mutants in toxic thyroid follicular adenomas.
Castro I; Lima L; Seoane R; Lado-Abeal J
Thyroid; 2009 Jun; 19(6):645-9. PubMed ID: 19499991
[TBL] [Abstract][Full Text] [Related]
11. Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (serine281-->isoleucine) in the extracellular domain of the thyrotropin receptor.
Kopp P; Muirhead S; Jourdain N; Gu WX; Jameson JL; Rodd C
J Clin Invest; 1997 Sep; 100(6):1634-9. PubMed ID: 9294132
[TBL] [Abstract][Full Text] [Related]
12. Hyperfunctioning thyroid adenoma and activating mutations in the TSH receptor gene.
Polak M
Arch Med Res; 1999; 30(6):510-3. PubMed ID: 10714365
[TBL] [Abstract][Full Text] [Related]
13. Genetic alterations in thyroid hyperfunctioning adenomas.
Russo D; Arturi F; Wicker R; Chazenbalk GD; Schlumberger M; DuVillard JA; Caillou B; Monier R; Rapoport B; Filetti S
J Clin Endocrinol Metab; 1995 Apr; 80(4):1347-51. PubMed ID: 7714109
[TBL] [Abstract][Full Text] [Related]
14. Functioning and nonfunctioning thyroid adenomas involve different molecular pathogenetic mechanisms.
Tonacchera M; Vitti P; Agretti P; Ceccarini G; Perri A; Cavaliere R; Mazzi B; Naccarato AG; Viacava P; Miccoli P; Pinchera A; Chiovato L
J Clin Endocrinol Metab; 1999 Nov; 84(11):4155-8. PubMed ID: 10566665
[TBL] [Abstract][Full Text] [Related]
15. Mutations of thyrotropin receptor gene.
Porcellini A; Fenzi G; Avvedimento EV
J Mol Med (Berl); 1997 Aug; 75(8):567-75. PubMed ID: 9297624
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism.
Duprez L; Parma J; Van Sande J; Allgeier A; Leclère J; Schvartz C; Delisle MJ; Decoulx M; Orgiazzi J; Dumont J
Nat Genet; 1994 Jul; 7(3):396-401. PubMed ID: 7920658
[TBL] [Abstract][Full Text] [Related]
17. Enhanced functional activity in thyroid adenomas in vitro.
Poertl S; Kirner J; Mann K; Hoermann R
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():39-40. PubMed ID: 8980999
[TBL] [Abstract][Full Text] [Related]
18. Constitutively activating mutations of the thyrotropin receptor and thyroid disease.
Führer D; Holzapfel HP; Wonerow P; Paschke R
Eur J Med Res; 1996 Jul; 1(10):460-4. PubMed ID: 9438142
[TBL] [Abstract][Full Text] [Related]
19. Mutations of thyrotropin receptor isolated from thyroid autonomous functioning adenomas confer TSH-independent growth to thyroid cells.
Porcellini A; Ruggiano G; Pannain S; Ciullo I; Amabile G; Fenzi G; Avvedimento EV
Oncogene; 1997 Aug; 15(7):781-9. PubMed ID: 9266964
[TBL] [Abstract][Full Text] [Related]
20. New pathophysiological mechanisms for hyperthyroidism.
Vassart G
Horm Res; 1997; 48 Suppl 4():47-50. PubMed ID: 9350447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
